ArticleInternational journal of general medicine2021
Prognostic Value of SLC16A3(MCT4) in Lung Adenocarcinoma and Its Clinical Significance.
Article in International journal of general medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 40 citations in OpenAlex.
- Association of glycolysis-related protein expression with prognosis in Canine Pulmonary Adenocarcinoma.The Journal of veterinary medical science · 2026Article
- SLC16A3 links tumor metabolism to therapeutic opportunities in hepatocellular carcinoma.Translational cancer research · 2026Review
- Solute carrier family 16 member 3 is a target of nodakenetin in breast cancer.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- SLC16A3 in lung adenocarcinoma regulates glycolysis and lactate release to facilitate M2 polarization of tumor-associated macrophages : Short Title: SLC16A3 reinforces macrophage M2 polarization through glycolysis.Cancer immunology, immunotherapy : CII · 2025Article
- Article
- Article
- SLC16A3 (MCT4) expression in tumor immunity and Metabolism: Insights from pan-cancer analysis.Biochemistry and biophysics reports · 2025Article
- Article
- Promotion of stem cell-like phenotype of lung adenocarcinoma by FAM83A via stabilization of ErbB2.Cell death & disease · 2024Article
- The anti-neoplastic effects of metformin modulate the acquired phenotype of fibroblast cells in the breast cancer-normal fibroblast co-culture system.Oncology research · 2024Article
- Genetic polymorphism of IL-18 influences susceptibility to lung cancer in population of eastern China.Journal of Cancer · 2024Article
- RAD54L promotes progression of hepatocellular carcinoma via the homologous recombination repair pathway.Functional & integrative genomics · 2023Article
- Elevated expression of TNFRSF4 impacts immune cell infiltration and gene mutation in hepatocellular carcinoma.Cancer biomarkers : section A of Disease markers · 2023Article
- Article
- Prognostic value ofFrontiers in oncology · 2023Article
- Identification of tumor-associated antigens and immune subtypes of lower-grade glioma and glioblastoma for mRNA vaccine development.Chinese neurosurgical journal · 2022Article
- Increased Expression of NXPH4 Correlates with Immune Cell Infiltration and Unfavorable Prognosis in Hepatocellular Carcinoma.Journal of oncology · 2022Article
- Transcriptome Analysis of Solute Carrier-Associated Genes in Hepatocellular Carcinoma: Friend or Foe?Frontiers in genetics · 2022Article
- The Overexpression of SLC25A13 Predicts Poor Prognosis and Is Correlated with Immune Cell Infiltration in Patients with Skin Cutaneous Melanoma.Disease markers · 2022Article
- Identification of Neoantigens and Construction of Immune Subtypes in Prostate Adenocarcinoma.Frontiers in genetics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCurrently, lung adenocarcinoma is the most common form of lung cancer. Although the pathogenesis of lung adenocarcinoma is progressing rapidly, the mortality rate of lung adenocarcinoma is still high. Therefore, it is necessary to search for a new biomarker to guide the prognosis of lung adenocarcinoma.
methodsThe significance of SLC16A3 in lung adenocarcinoma was investigated by multi-database analysis. GEPIA, UALCAN, TIMER, Cbioportal, and R software were used for research.
resultsOur study found that SLC16A3 was highly expressed in lung adenocarcinoma and was associated with poor prognosis. Further studies have shown that SLC16A3 is involved in some metabolic pathways. Not only that, SLC16A3 is associated with immune cell infiltration and tumor mutation burden (TMB).
conclusionSLC16A3 has good prognostic significance in lung adenocarcinoma, based on which to explore treatment options may improve the prognosis of patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.